1.
J Obstet Gynaecol Can
; 46(3): 102299, 2024 Mar.
Article
in English
| MEDLINE
| ID: mdl-38548447
2.
J Obstet Gynaecol Can
; 46(1): 102189, 2024 01.
Article
in English
| MEDLINE
| ID: mdl-37558164
3.
Clin Lab Med
; 41(1): 133-151, 2021 03.
Article
in English
| MEDLINE
| ID: mdl-33494881
ABSTRACT
Hemolytic disease of the fetus and newborn (HDFN) is an immune-mediated disorder affecting neonates globally, with a range of clinical presentations from severe and life threatening to mild or even asymptomatic. Historically, HDFN has been responsible for a large proportion of perinatal mortality, and, despite advances in diagnosis and management, this morbidity and mortality has not been eradicated. Blood banking techniques and blood transfusion have contributed to improved prophylaxis and management, drastically improving the outcome of newborns with HDFN over the last century.